Silencing of circRACGAP1 sensitizes gastric cancer cells to apatinib via modulating autophagy by targeting miR-3657 and ATG7

The positive results of the apatinib phase III trial have cast new light on treatment for patients with advanced gastric cancer (GC). However, in terms of safety, apatinib toxicities may lead to a dose modification or treatment interruption. Therefore, proper intervention is urgently needed to help...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Ling, Wang, Zhangding, Xie, Mengyan, Quan, Yunlin, Zhu, Weiyou, Yang, Fengming, Zhao, Chenhui, Fan, Yu, Fang, Na, Jiang, Huning, Wang, Qiang, Wang, Shouyu, Zhou, Jianwei, Chen, Xiaofeng, Shu, Yongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058073/
https://www.ncbi.nlm.nih.gov/pubmed/32139670
http://dx.doi.org/10.1038/s41419-020-2352-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058073/
https://www.ncbi.nlm.nih.gov/pubmed/32139670
http://dx.doi.org/10.1038/s41419-020-2352-0

Ejemplares similares